Progesterone pharmacokinetics in the mouse: Implications for potential stroke therapy

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 11, 2012, Pages 1614-1620

  Wong, Raymond ^a   Ray, David ^a   Kendall, David A ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

brain; pharmacokinetics; plasma; progesterone; stroke

Indexed keywords

DIMETHYL SULFOXIDE; PROGESTERONE;

ANIMAL EXPERIMENT; ARTICLE; BOLUS INJECTION; BRAIN ISCHEMIA; C57BL 6 MOUSE; CEREBROVASCULAR ACCIDENT; CONTINUOUS INFUSION; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; MALE; MOUSE; NERVOUS SYSTEM INJURY; NEUROPROTECTION; NONHUMAN; OSMOTIC MINIPUMP; OUTCOME ASSESSMENT;

ANIMALS; BRAIN; DIMETHYL SULFOXIDE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HALF-LIFE; INFUSION PUMPS, IMPLANTABLE; INFUSIONS, SUBCUTANEOUS; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; PROGESTERONE; STROKE; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 84867581389     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01537.x     Document Type: Article

References (50)

1. Wolfe C, et al,. Stroke Services and Research: An Overview with Recommendations for Future Research. London: The Stroke Association, 1996.
2. Adamson J, et al,. Is stroke the most common cause of disability ? J Stroke Cerebrovasc Dis 2004; 13: 171-177.
3. Appelros P, et al,. Sex differences in stroke epidemiology a systematic review. Stroke 2009; 40: 1082-1090.
4. Barrett-Connor E, Bush TL,. Estrogen and coronary heart disease in women. JAMA 1991; 265: 1861-1867.
5. Kannel WB, Thom TJ,. The incidence, prevalence and mortality of cardiovascular disease. In:, Schlant RC, Alexander RW, eds. The Heart. New York: McGraw-Hill Inc, 1994: 185-197.
6. Wenger N, et al,. Cardiovascular health and disease in women. N Engl J Med 1993; 329: 247-256.
7. Gibson CL, et al,. Estrogen and experimental ischemic stroke: a systematic review. J Cereb Blood Flow Metab 2006; 26: 1103-1113.
8. Alkayed NJ, et al,. Neuroprotective effects of female gonadal steroids in reproductively senescent female rats. Stroke 2000; 31: 161-168.
9. Gibson CL, Murphy S,. Progesterone enhances functional recovery after middle cerebral artery occlusion in male mice. J Cereb Blood Flow Metab 2004; 24: 805-813.
10. Jiang N, et al,. Progesterone is neuroprotective after transient middle cerebral artery occlusion in male rats. Brain Res 1996; 735: 101-107.
11. Kumon Y, et al,. Neuroprotective effect of postischemic administration of progesterone in spontaneously hypertensive rats with focal cerebral ischemia. J Neurosurg 2000; 92: 848-852.
12. Murphy SJ, et al,. Progesterone administration during reperfusion, but not preischemia alone, reduces injury in ovariectomized rats. J Cereb Blood Flow Metab 2002; 22: 1181-1188.
13. Gibson CL, et al,. Progesterone supresses the inflammatory response and nitric oxide synthase-2 expression following cerebral ischemia. Exp Neurol 2005; 193: 522-530.
14. Sayeed I, et al,. Progesterone inhibits ischemic brain injury in a rat model of permanent middle cerebral artery occlusion. Restor Neurol Neurosci 2007; 25: 151-159.
15. Sayeed I, et al,. Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism for better neuroprotective effects of allopregnanolone over progesterone. Brain Res 2009; 1263: 165-173.
16. Ishrat T, et al,. Effects of progesterone administration on infarct volume and functional deficits following permanent focal cerebral ischemia in rats. Brain Res 2009; 1257: 94-101.
17. Chen J, Chopp M,. Neuroprotective effects of progesterone after transient middle cerebral artery occlusion in rat. J Neurol Sci 1999; 171: 24-30.
18. Gibson CL, et al,. Progesterone for the treatment of experimental brain injury; a systematic review. Brain 2007; 131: 318-328.
19. Sharpe C, Boivin JF,. The etiology of female breast cancer. Med Princ Pract 2000; 9: 1-24.
20. Little BC, et al,. Physiological and psychological effects of progesterone in man. J Nerv Ment Dis 1974; 159: 256-262.
21. Gaver RC, et al,. Bioequivalence evaluation of new megestrol-acetate formulations in humans. Semin Oncol 1985; 12: 17-19.
22. Goletiani NV, et al,. Progesterone: review of safety for clinical studies. Exp Clin Psychopharmacol 2007; 15: 427-444.
23. Wright DW, et al,. ProTECT: a randomized clinical trial of progresterone for acute traumatic brain injury. Ann Emerg Med 2007; 49: 391-402.
24. Xiao GM, et al,. Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Crit Care 2008; 12: R61.
25. Murphy SJ, et al,. Progesterone exacerbates striatal stroke injury in progesterone deficient female animals. Stroke 2000; 31: 1173-1178.
26. Coomber B, Gibson CL,. Sustained levels of progesterone prior to the onset of cerebral ischemia are not beneficial to female mice. Brain Res 2010; 1361: 124-132.
27. Ginsberg MD,. Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology 2008; 55: 363-389.
28. Frye CA, et al,. The neurosteroids, progesterone and 3 alpha,5 alpha-THP, enhance sexual motivation, receptivity, and proceptivity in female rats. Brain Res 1998; 808: 72-83.
29. Vengpedersen P,. Mean time parameters in pharmacokinetics-definition, computation and clinical implications.2. Clin Pharmacokinet 1989; 17: 424-440.
30. Gibaldi M, Perrier B,. Pharmacokinetics, 2 edn. New York: Marcel Dekker, 1982. 433.
31. Martin BK,. Pharmacokinetics. In:, Glenny H, Nelmes P, eds. Handbook of Clinical Drug Research. London: Blackwell Scientific Publications, 1986: 59-93.
32. Roof RL, et al,. Progesterone treatment attenuates brain edema following contusion injury in male and female rats. Restor Neurol Neurosci 1992; 4: 425-427.
33. Roof RL, et al,. Progesterone rapidly decreases brain edema: treatment delayed up to 24 hours is still effective. Exp Neurol 1996; 138: 246-251.
34. Beckley EH, Finn DA,. Inhibition of progesterone metabolism mimics the effect of progesterone withdrawal on forced swim test immobility. Pharmacol Biochem Behav 2007; 87: 412-419.
35. Gibson CL, et al,. Progesterone is neuroprotective following cerebral ischaemia in reproductively ageing female mice. Brain 2011; 134: 2125-2133.
36. Zhu D, et al,. Dynamic aspects of acute tolerance to allopregnanolone evaluated using anaesthesia threshold in male rats. Br J Anaesth 2004; 93: 560-567.
37. Schumacher M, et al,. Steroid synthesis and metabolism in the nervous system: trophic and protective effects. J Neurocytol 2000; 29: 307-326.
38. Pardridge WM, Mietus LJ,. Transport of steroid hormones through the rat blood-brain barrier. Primary role of albumin-bound hormone. J Clin Invest 1979; 64: 145-154.
39. Billiar RB, et al,. The metabolic clearance rate, head and brain extractions, and brain distribution and metabolism of progesterone in anesthetized, female monkey (Macaca mulatta). Brain Res 1975; 94: 99-113.
40. Johnson WA, et al,. Head extractions, brain and pituitary uptake and metabolism of progesterone and 5alpha-dihydroprogesterone in anesthetized, female rabbits. Brain Res 1976; 111: 147-155.
41. Lephart ED, et al,. Brain androgen and progesterone metabolizing enzymes: biosynthesis, distribution and function. Brain Res Rev 2001; 37: 25-37.
42. Sayeed I, et al,. Allopregnanolone, a progesterone metabolite, is more effective than progesterone in reducing cortical infarct volume after transient middle cerebral artery occlusion. Ann Emerg Med 2006; 47: 381-389.
43. Lobo RA, et al,. Progestogen matabolism. In:, Lobo RA, et al., ed. Menopause: Biology and Pathobiology. San Diego: Academic Press, 2000: 422-434.
44. McCormac JT, Greenwal GS,. Progesterone and estradiol-17beta concentrations in peripheral plasma during pregnancy in mouse. J Endocrinol 1974; 62: 101-107.
45. Virgo BB, Bellward GD,. Serum progesterone levels in the pregnant and postpartum laboratory mouse. Endocrinology 1974; 95: 1486-1490.
46. Corpechot C, et al,. Brain neurosteroids during the mouse oestrous cycle. Brain Res 1997; 766: 276-280.
47. Falcao ALE, et al,. The resistance to ischemia of white and gray matter after stroke. Ann Neurol 2004; 56: 695-701.
48. Ho PW, et al,. Is white matter involved in patients entered into typical trials of neuroprotection? Stroke 2005; 36: 2742-2744.
49. Cheng YD, et al,. Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRX 2004; 1: 36-45.
50. Green AR, et al,. Animal models of stroke: do they have value for discovering neuroprotective agents? Trends Pharmacol Sci 2003; 24: 402-408.